Physician profile
Derek C Hindman
NPI 1447242334
$3,373.33
in general payments reported to CMS, 2019-2025
13 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $173 · 2021: $1,573 · 2022: $787 · 2023: $53.71 · 2024: $102 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,623.90 | 2019-2023 | Viaflow, Fixos |
| Convatec INC. | $158.64 | 2025 | |
| Abbott Laboratories | $123.81 | 2021-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $122.34 | 2019 | |
| Novo Nordisk INC | $67.61 | 2019-2021 | |
| Abbvie INC. | $63.30 | 2021-2022 | |
| Glaxosmithkline, LLC. | $50.66 | 2024-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $49.23 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $33.74 | 2025 | Farxiga |
| Lilly USA, LLC | $29.97 | 2021-2023 | Mounjaro |
| Paratek Pharmaceuticals, INC. | $20.46 | 2025 | Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.65 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Hindman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.